These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 18408020)

  • 21. IFN-beta inhibits human Th17 cell differentiation.
    Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
    J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis.
    Comabella M; Río J; Espejo C; Ruiz de Villa M; Al-Zayat H; Nos C; Deisenhammer F; Baranzini SE; Nonell L; López C; Julià E; Oksenberg JR; Montalban X
    Clin Immunol; 2009 Feb; 130(2):145-50. PubMed ID: 18945642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells.
    Iglesias AH; Camelo S; Hwang D; Villanueva R; Stephanopoulos G; Dangond F
    J Neuroimmunol; 2004 May; 150(1-2):163-77. PubMed ID: 15081262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
    Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
    J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
    Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
    Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?
    Sorensen PS; Koch-Henriksen N; Bendtzen K
    Mult Scler; 2007 Jun; 13(5):616-21. PubMed ID: 17548440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon beta-1a induces tumor necrosis factor receptor 1 but decreases tumor necrosis factor receptor 2 leukocyte mRNA levels in relapsing-remitting multiple sclerosis.
    Reuss R; Pohle S; Retzlaff K; Hemberger J; Oschmann P
    Neuroimmunomodulation; 2009; 16(3):171-6. PubMed ID: 19246939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
    Goertsches RH; Hecker M; Koczan D; Serrano-Fernandez P; Moeller S; Thiesen HJ; Zettl UK
    Pharmacogenomics; 2010 Feb; 11(2):147-61. PubMed ID: 20136355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-beta1b in multiple sclerosis: effect on progression of disability and clinical markers of treatment response.
    Carmona O; Casado V; Moral E; Alonso-Magdalena L; Martínez-Yélamos A; Martínez-Yélamos S; Martín-Ozaeta G; Arbizu T
    Eur Neurol; 2008; 60(6):279-84. PubMed ID: 18824855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New natural history of interferon-beta-treated relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Fuiani A; Paolicelli D; Zipoli V; Zimatore GB; Di Monte E; Portaccio E; Lepore V; Livrea P; Amato MP
    Ann Neurol; 2007 Apr; 61(4):300-6. PubMed ID: 17444502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of season on cytokine expression in multiple sclerosis and healthy subjects.
    Stewart N; Taylor B; Ponsonby AL; Pittas F; van der Mei I; Woods G; Walters H
    J Neuroimmunol; 2007 Aug; 188(1-2):181-6. PubMed ID: 17628701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients.
    Vallittu AM; Erälinna JP; Ilonen J; Salmi AA; Waris M
    Acta Neurol Scand; 2008 Jul; 118(1):12-7. PubMed ID: 18081914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.
    Byun E; Caillier SJ; Montalban X; Villoslada P; Fernández O; Brassat D; Comabella M; Wang J; Barcellos LF; Baranzini SE; Oksenberg JR
    Arch Neurol; 2008 Mar; 65(3):337-44. PubMed ID: 18195134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
    Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
    Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
    Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
    Clin Immunol; 2006 Jan; 118(1):77-82. PubMed ID: 16275091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis.
    Zaffaroni M; Marino F; Bombelli R; Rasini E; Monti M; Ferrari M; Ghezzi A; Comi G; Lecchini S; Cosentino M
    Exp Neurol; 2008 Dec; 214(2):315-21. PubMed ID: 18824168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.